ANG-3777: A SMALL MOLECULE
ANG-3777 MIMICS, SUPPLEMENTS, AND ENHANCES THE EFFECTS OF HGF
ANG-3777 mimics hepatocyte growth factor (HGF) to prevent cell death, activate self-repair and stimulate regeneration following organ injury. ANG-3777 extends the body’s window for therapeutic intervention in the setting of organ injury. Unlike other therapies, it is effective even when dosed 24 hours or beyond organ damage.
ANG-3777’s effectiveness when dosed after injury is a critical differentiating factor both in terms of clinical trial design and therapeutic window for treatment.
• When injury occurs in AKI, HGF is immediately released from storage (blue line) and the body’s reserves are significantly depleted.
• An upregulation of c-Met starts at time of injury (red line).
• At 24 hours (light blue bar), there is maximal expression of c-Met receptors presenting an opportunity to enhance the critical activity of this anti-cell death and regenerative pathway.
• ANG-3777, a small organic molecule, is an HGF mimetic.
• Dosing with ANG-3777 at 24, 48, and 72 hours supplements the depleted HGF, binding with the underutilized but upregulated c-Met receptors.
• By enhancing the kidney’s ability to self-repair, ANG-3777 prevents and reduces further renal injury.
ANG-3777 & DELAYED GRAFT FUNCTION ASSOCIATED ACUTE KIDNEY INJURY
A phase 2 trial investigating ANG-3777 in delayed graft function associated acute kidney injury (DGF-AKI) demonstrated improved clinical outcomes in patients when given within 36 hours of renal transplant. Treatment demonstrated improved urine production and kidney function. The ANG-3777 treated group had a 36% reduction in duration of DGF.
A phase 3 trial of ANG-3777 in DGF is currently enrolling.
ANG-3777 & CARDIAC SURGERY ASSOCIATED ACUTE KIDNEY INJURY
More than 350,000 cardiac surgeries are performed annually in the U.S. Cardiac surgery associated AKI (CSA-AKI) is the most common significant complication that develops after cardiac surgery. Developing this condition leads to a doubling of morbidity and mortality in affected patients and severe cases of CSA-AKI may generate mortality rates of up to 50%. The current standard of care is increased hospitalization and dialysis.
A phase 2 trial investigating ANG-3777 for the treatment of CSA-AKI is currently enrolling.
Additional potential indications for ANG-3777 include stroke, corneal scarring, heart injury, acute lung injury, and acute liver injury.